Victory Capital Management
ATXS

Victory Capital Management’s Astria Therapeutics ATXS Stock Holding History

Victory Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,799
Closed -$23K – 2779
2021
Q2 		$23K Buy
+1,799
New +$23.4K ﹤0.01% 2701
2020
Q2 		– Sell
-992
Closed -$24K – 2570
2020
Q1 		$24K Buy
+992
New +$30.8K ﹤0.01% 3028
2019
Q4 		– Sell
-331
Closed -$11K – 2687
2019
Q3 		$11K Buy
+331
New +$13.1K ﹤0.01% 3217

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Victory Capital Management's ATXS Position: Q3 2021 in Review

Victory Capital Management sold out of Astria Therapeutics (ATXS) in Q3 2021, closing a stake of 1,799 shares — an estimated $23K sold.

Victory Capital Management first reported a position in ATXS in Q3 2019 and held it in 3 quarters. The position peaked at $24K in Q1 2020. 35 funds tracked by Wall St. Rank hold ATXS as of Q3 2021.

  • Victory Capital Management reported no remaining Astria Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Victory Capital Management sold 1,799 Astria Therapeutics shares in Q3 2021, an estimated $23K.
  • Victory Capital Management first reported a position in Astria Therapeutics in Q3 2019 and held it in 3 quarters.
  • Victory Capital Management's Astria Therapeutics position peaked at $24K in Q1 2020.
  • 35 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2021.

Based on Victory Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.